{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:57:36Z","timestamp":1790830656008,"version":"4.1.0"},"reference-count":94,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease with increased alcohol consumption (MetALD) is a newly defined category within the spectrum of steatotic liver disease. It captures patients who have both cardiometabolic risk factors and alcohol intake above the thresholds accepted for metabolic dysfunction-associated steatotic liver disease (MASLD). This overlap matters clinically, as the coexistence of metabolic dysfunction and increased alcohol exposure is associated with a higher risk of progressive liver disease. In this narrative review, we bring together current evidence on the diagnosis, non-invasive risk stratification, and management of MetALD, with particular attention to serum-based fibrosis scores such as the Fibrosis-4 (FIB-4) index and imaging-based methods including vibration-controlled transient elastography and controlled attenuation parameter. We also consider the factors that can complicate the interpretation of these non-invasive tests when alcohol use is ongoing. Management has to address both components of the disease at once: reducing alcohol exposure, treating alcohol use disorder where present, managing weight, and controlling cardiometabolic risk factors. Incretin-based therapies are attracting growing interest given their established metabolic effects and the emerging hepatic and alcohol-related data, though no randomized trial has yet tested their efficacy specifically in MetALD. In advanced disease, liver transplantation remains the definitive option for appropriately selected patients, but it requires careful assessment of cardiometabolic comorbidities, alcohol-related risk, and frailty. Further prospective studies are needed to clarify the natural history of MetALD, define optimal risk-stratification strategies, and establish treatment outcomes in this population.<\/jats:p>","DOI":"10.3390\/jcm15197540","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:50:54Z","timestamp":1790614254000},"page":"7540","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MetALD in Clinical Practice: Diagnosis, Non-Invasive Risk Stratification, and Management"],"prefix":"10.3390","volume":"15","author":[{"given":"Hubert","family":"Krzewi\u0144ski","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru\u0144, 85-067 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliwier","family":"W\u0105troba","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru\u0144, 85-067 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw","family":"Koza","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Nutrition Disorders, Faculty of Health Sciences, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru\u0144, 85-168 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease","volume":"64","author":"Marchesini","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the Global Public Health Agenda for NAFLD: A Consensus Statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101250","DOI":"10.1016\/j.jhepr.2024.101250","article-title":"MetALD: Clinical Aspects, Pathophysiology and Treatment","volume":"7","author":"Bataller","year":"2025","journal-title":"JHEP Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"goag006","DOI":"10.1093\/gastro\/goag006","article-title":"MetALD: Decoding the Evolution of Steatotic Liver Disease Nomenclature and Implications for Clinical Practice and Beyond","volume":"14","author":"Ghodrati","year":"2026","journal-title":"Gastroenterol. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jhep.2024.11.028","article-title":"Metabolic Dysfunction and Alcohol-Related Liver Disease (MetALD): Position Statement by an Expert Panel on Alcohol-Related Liver Disease","volume":"82","author":"Arab","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 Global Prevalence of Nonalcoholic Fatty Liver Disease Using Hierarchical Bayesian Approach","volume":"28","author":"Le","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.20517\/mtod.2025.234","article-title":"Definition, Prevalence, and Healthcare Burden of MetALD\u2014A Comprehensive Assessment of Epidemiology from the East and West","volume":"6","author":"Zhou","year":"2026","journal-title":"Metab. Target Organ Damage"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"156101","DOI":"10.1016\/j.metabol.2024.156101","article-title":"Prevalence, Characteristics and Outcomes of Patients with Metabolic and Alcohol Related\/Associated Liver Disease (MetALD): A Systematic Review and Meta-Analysis","volume":"163","author":"Tampaki","year":"2025","journal-title":"Metabolism"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1159\/000535943","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study","volume":"13","author":"Kim","year":"2024","journal-title":"Liver Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"101639","DOI":"10.1016\/j.jhepr.2025.101639","article-title":"Hepatocellular Carcinoma Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake (MetALD)","volume":"8","author":"John","year":"2026","journal-title":"JHEP Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e100319","DOI":"10.1136\/egastro-2025-100319","article-title":"Metabolic Dysfunction and Alcohol-Associated Liver Disease (MetALD)","volume":"3","author":"Gao","year":"2025","journal-title":"eGastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.31518","article-title":"Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"agaf014","DOI":"10.1093\/alcalc\/agaf014","article-title":"The Role of Cytochrome P4502E1 in Ethanol Mediated Diseases: A Narrative Update","volume":"60","author":"Zakhari","year":"2025","journal-title":"Alcohol Alcohol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Arumugam, M.K., Gopal, T., Kalari Kandy, R.R., Boopathy, L.K., Perumal, S.K., Ganesan, M., Rasineni, K., Donohue, T.M., Osna, N.A., and Kharbanda, K.K. (2023). Mitochondrial Dysfunction-Associated Mechanisms in the Development of Chronic Liver Diseases. Biology, 12.","DOI":"10.3390\/biology12101311"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.toxrep.2023.10.005","article-title":"Alcohol-Induced Liver Injury in Signalling Pathways and Curcumin\u2019s Therapeutic Potential","volume":"11","author":"Subramaniyan","year":"2023","journal-title":"Toxicol. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12967-023-04166-8","article-title":"Pathogenic Mechanisms and Regulatory Factors Involved in Alcoholic Liver Disease","volume":"21","author":"Yan","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Hyun, J., Han, J., Lee, C., Yoon, M., and Jung, Y. (2021). Pathophysiological Aspects of Alcohol Metabolism in the Liver. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115717"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.35946\/arcr.v38.2.02","article-title":"Alcohol and Gut-Derived Inflammation","volume":"38","author":"Bishehsari","year":"2017","journal-title":"Alcohol Res."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Elamin, E., Jonkers, D., Juuti-Uusitalo, K., van Ijzendoorn, S., Troost, F., Duimel, H., Broers, J., Verheyen, F., Dekker, J., and Masclee, A. (2012). Effects of Ethanol and Acetaldehyde on Tight Junction Integrity: In Vitro Study in a Three Dimensional Intestinal Epithelial Cell Culture Model. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035008"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ha, Y., Jeong, I., and Kim, T.H. (2022). Alcohol-Related Liver Disease: An Overview on Pathophysiology, Diagnosis and Therapeutic Perspectives. Biomedicines, 10.","DOI":"10.3390\/biomedicines10102530"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"R199","DOI":"10.1530\/JME-13-0277","article-title":"Dissecting Adipose Tissue Lipolysis: Molecular Regulation and Implications for Metabolic Disease","volume":"52","author":"Nielsen","year":"2014","journal-title":"J. Mol. Endocrinol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.biochi.2015.10.024","article-title":"Adipocyte Lipolysis and Insulin Resistance","volume":"125","author":"Morigny","year":"2016","journal-title":"Biochimie"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"100346","DOI":"10.1016\/j.jhepr.2021.100346","article-title":"New Targets for NAFLD","volume":"3","author":"Parlati","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin Resistance Drives Hepatic de Novo Lipogenesis in Nonalcoholic Fatty Liver Disease","volume":"130","author":"Smith","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"964","DOI":"10.4093\/dmj.2025.0644","article-title":"Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications","volume":"49","author":"Truong","year":"2025","journal-title":"Diabetes Metab. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.ajpath.2023.08.007","article-title":"The Role of Endoplasmic Reticulum in Lipotoxicity during Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Pathogenesis","volume":"193","author":"Venkatesan","year":"2023","journal-title":"Am. J. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/hep.30252","article-title":"NLR Family Pyrin Domain-Containing 3 Inflammasome Activation in Hepatic Stellate Cells Induces Liver Fibrosis in Mice","volume":"69","author":"Inzaugarat","year":"2019","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1055\/a-2630-0952","article-title":"MetALD: Genetic Factors and Clinical Outcomes","volume":"45","author":"Israelsen","year":"2025","journal-title":"Semin. Liver Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/ueg2.12370","article-title":"Influence of Sex in Alcohol-Related Liver Disease: Pre-Clinical and Clinical Settings","volume":"11","author":"Bizzaro","year":"2023","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"17562848251331315","DOI":"10.1177\/17562848251331315","article-title":"A Comprehensive Analysis of the Impact of Smoking on Adverse Clinical Outcomes of Steatotic Liver Diseases","volume":"18","author":"Yang","year":"2025","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_35","first-page":"100016","article-title":"Serum Fibrosis Scores as Predictors of Liver Fibrosis and Long-Term Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease, Including Cirrhosis","volume":"77","author":"Bengi","year":"2025","journal-title":"Rev. Investig. Cl\u00edn."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"113475","DOI":"10.4254\/wjh.v18.i1.113475","article-title":"Blood Markers vs Transient Elastography for Liver Stiffness and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"18","author":"Joseph","year":"2026","journal-title":"World J. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.gastro.2026.01.047","article-title":"Clinical Care Pathway for the Risk Stratification and Management of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"171","author":"Kanwal","year":"2026","journal-title":"Gastroenterology"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Roy, A., Jajodia, S., Chakraborty, S., Keyal, S., Tewari, A., Sonthalia, N., Roy, S., Khandelwal, R., Kulkarni, A., and Ghoshal, U.C. (2026). Blood-Based Non-Invasive Tests Show Comparable Accuracy in MetALD and MASLD for MRE-Defined Advanced Fibrosis. BMC Gastroenterol., 26.","DOI":"10.1186\/s12876-026-04839-w"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e01020","DOI":"10.1097\/HC9.0000000000001020","article-title":"Global Multicenter Validation of Noninvasive Fibrosis Assessment Pathways in MetALD and ALD","volume":"10","author":"Gu","year":"2026","journal-title":"Hepatol. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/apt.70281","article-title":"MetALD: Diagnosis and Prognosis with Non-Invasive Tests","volume":"62","author":"Torp","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a Simple Noninvasive Index to Predict Significant Fibrosis in Patients with HIV\/HCV Coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients with Chronic Hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"ref_43","first-page":"322","article-title":"A Clinical Review of Noninvasive Tests for Hepatic Fibrosis","volume":"20","author":"Chadha","year":"2024","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"101062","DOI":"10.1016\/j.jhepr.2024.101062","article-title":"Enhanced Liver Fibrosis (ELF) Score Predicts Hepatic Decompensation and Mortality","volume":"6","author":"Pearson","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"100765","DOI":"10.1016\/j.jhepr.2023.100765","article-title":"Enhanced Liver Fibrosis\u00ae Test Predicts Liver-Related Outcomes in the General Population","volume":"5","author":"Saarinen","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cld.2024.06.009","article-title":"Diagnosis of Alcohol Use Disorder and Alcohol-Associated Liver Disease","volume":"28","author":"Witkiewitz","year":"2024","journal-title":"Clin. Liver Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jceh.2022.10.002","article-title":"Spectrum, Screening, and Diagnosis of Alcohol-Related Liver Disease","volume":"13","author":"Bataller","year":"2023","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.alcohol.2020.02.166","article-title":"Alcohol-Induced Thrombocytopenia: Current Review","volume":"86","author":"Silczuk","year":"2020","journal-title":"Alcohol"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Mih\u0103il\u0103, D., Domnariu, H.-P., Moga, D.-F.-C., and Domnariu, C.-D. (2026). Alcohol Abstinence Is Associated with Regression of Non-Invasive Fibrosis Markers in Patients with Metabolic Syndrome: A 12-Month Prospective Study. J. Clin. Med., 15.","DOI":"10.3390\/jcm15062257"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on Non-Invasive Tests for Evaluation of Liver Disease Severity and Prognosis\u20142021 Update","volume":"75","author":"Berzigotti","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1055\/s-0043-103952","article-title":"EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version)","volume":"38","author":"Dietrich","year":"2017","journal-title":"Ultraschall Med. J. Ultrasound"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00261-018-1475-6","article-title":"Principles of Ultrasound Elastography","volume":"43","author":"Ozturk","year":"2018","journal-title":"Abdom. Radiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/hep.25993","article-title":"Determination of Reliability Criteria for Liver Stiffness Evaluation by Transient Elastography","volume":"57","author":"Boursier","year":"2013","journal-title":"Hepatology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII Faculty. Baveno VII\u2014Renewing Consensus in Portal Hypertension","volume":"76","author":"Bosch","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual Patient Data Meta-Analysis of Controlled Attenuation Parameter (CAP) Technology for Assessing Steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.24452","article-title":"Diagnostic Accuracy and Reliability of Ultrasonography for the Detection of Fatty Liver: A Meta-Analysis","volume":"54","author":"Hernaez","year":"2011","journal-title":"Hepatology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.29797","article-title":"Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials","volume":"68","author":"Caussy","year":"2018","journal-title":"Hepatology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3748\/wjg.v16.i8.966","article-title":"Increased Liver Stiffness in Alcoholic Liver Disease: Differentiating Fibrosis from Steatohepatitis","volume":"16","author":"Mueller","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.cgh.2021.02.021","article-title":"Transient Elastography Accurately Screens for Compensated Advanced Chronic Liver Disease in Patients with Ongoing or Recent Alcohol Withdrawal","volume":"20","author":"Legros","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3748\/wjg.v19.i4.516","article-title":"Effect of Alcohol Consumption on Liver Stiffness Measured by Transient Elastography","volume":"19","author":"Legros","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.cgh.2007.06.012","article-title":"Assessment of Hepatic Fibrosis with Magnetic Resonance Elastography","volume":"5","author":"Yin","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1053\/j.gastro.2016.01.017","article-title":"Magnetic Resonance Imaging\/Elastography Is Superior to Transient Elastography for Detection of Liver Fibrosis and Fat in Nonalcoholic Fatty Liver Disease","volume":"150","author":"Taouli","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1148\/radiol.2016160863","article-title":"Technical Failure of MR Elastography Examinations of the Liver: Experience from a Large Single-Center Study","volume":"284","author":"Wagner","year":"2017","journal-title":"Radiology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) Score for the Non-Invasive Identification of Patients with Non-Alcoholic Steatohepatitis with Significant Activity and Fibrosis: A Prospective Derivation and Global Validation Study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jhep.2022.10.034","article-title":"Enhanced Diagnosis of Advanced Fibrosis and Cirrhosis in Individuals with NAFLD Using FibroScan-Based Agile Scores","volume":"78","author":"Sanyal","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective Evaluation of a Primary Care Referral Pathway for Patients with Non-Alcoholic Fatty Liver Disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/HEP.0000000000000635","article-title":"Validation of AGA Clinical Care Pathway and AASLD Practice Guidance for Nonalcoholic Fatty Liver Disease in a Prospective Cohort of Patients with Type 2 Diabetes","volume":"79","author":"Ajmera","year":"2024","journal-title":"Hepatology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1111\/liv.13480","article-title":"Serum Biomarkers Can Predict a Change in Liver Fibrosis 1 Year after Lifestyle Intervention for Biopsy-proven NASH","volume":"37","author":"Friedman","year":"2017","journal-title":"Liver Int."},{"key":"ref_69","unstructured":"European Association for the Study of the Liver (2025). EASL Clinical Practice Guidelines on the Management of Hepatocellular Carcinoma. J. Hepatol., 82, 315\u2013374."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance from the American Association for the Study of Liver Diseases","volume":"71","author":"Crabb","year":"2020","journal-title":"Hepatology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"30","DOI":"10.14309\/ajg.0000000000002572","article-title":"ACG Clinical Guideline: Alcohol-Associated Liver Disease","volume":"119","author":"Jophlin","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_72","first-page":"CD012557","article-title":"Baclofen for Alcohol Use Disorder","volume":"1","author":"Agabio","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"101095","DOI":"10.1016\/j.jhepr.2024.101095","article-title":"Safety of Naltrexone in Patients with Cirrhosis","volume":"6","author":"Thompson","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis","volume":"149","author":"Friedman","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Phase 2a Trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-Weekly Semaglutide in Adults with Alcohol Use Disorder: A Randomized Clinical Trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(26)00305-3","article-title":"Once-Weekly Semaglutide versus Placebo in Patients with Alcohol Use Disorder and Comorbid Obesity: A Randomised, Double-Blind, Placebo-Controlled Trial","volume":"407","author":"Klausen","year":"2026","journal-title":"Lancet"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2.4 mg Once Weekly in Patients with Non-Alcoholic Steatohepatitis-Related Cirrhosis: A Randomised, Placebo-Controlled Phase 2 Trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1111\/dom.16275","article-title":"Body Composition Changes during Weight Reduction with Tirzepatide in the SURMOUNT-1 Study of Adults with Obesity or Overweight","volume":"27","author":"Look","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/HEP.0000000000000914","article-title":"Waitlisting and Liver Transplantation for MetALD in the United States: An Analysis of the UNOS National Registry","volume":"81","author":"Serper","year":"2025","journal-title":"Hepatology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/jcsm.12039","article-title":"Sarcopenic Obesity and Myosteatosis Are Associated with Higher Mortality in Patients with Cirrhosis","volume":"7","author":"Angulo","year":"2016","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2024.07.032","article-title":"EASL Clinical Practice Guidelines on Liver Transplantation","volume":"81","author":"Samuel","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e0892","DOI":"10.1097\/HC9.0000000000000892","article-title":"Clinical Outcomes in MetALD Compared with ALD in Patients Referred for Liver Transplant Evaluation","volume":"10","author":"Ibrahim","year":"2026","journal-title":"Hepatol. Commun."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jhep.2024.03.031","article-title":"Acute Kidney Injury in Patients with Cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) Joint Multidisciplinary Consensus Meeting","volume":"81","author":"Nadim","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1093\/eurheartj\/ehae502","article-title":"Cardiovascular Disease Assessment and Management in Liver Transplantation","volume":"45","author":"Harinstein","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1097\/HEP.0000000000001644","article-title":"AASLD AST Practice Guideline on Adult Liver Transplantation: Candidate Evaluation","volume":"83","author":"Dove","year":"2026","journal-title":"Hepatology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.psym.2011.12.012","article-title":"The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT): A New Tool for the Psychosocial Evaluation of Pre-Transplant Candidates","volume":"53","author":"Maldonado","year":"2012","journal-title":"Psychosomatics"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/ADM.0000000000001424","article-title":"False-Positive Phosphatidylethanol Results Due to Blood Transfusion and Implications in the Process of Liver Transplantation Selection","volume":"19","author":"Wang","year":"2025","journal-title":"J. Addict. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2010.01.040","article-title":"Metabolic Syndrome and Liver Transplantation: A Review and Guide to Management","volume":"53","author":"Watt","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/LVT.0000000000000785","article-title":"AASLD AST Practice Guideline on Adult Liver Transplantation: Diagnosis and Post-Transplant Management of Non-Graft\u2013Related Complications","volume":"32","author":"Sharma","year":"2026","journal-title":"Liver Transplant."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/hep.31496","article-title":"A Randomized Clinical Trial of Fecal Microbiota Transplant for Alcohol Use Disorder","volume":"73","author":"Bajaj","year":"2021","journal-title":"Hepatology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2541035","DOI":"10.1080\/19490976.2025.2541035","article-title":"Consecutive Fecal Microbiota Transplantation for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial","volume":"17","author":"Groenewegen","year":"2025","journal-title":"Gut Microbes"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7540\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:28:51Z","timestamp":1790828931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":94,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["jcm15197540"],"URL":"https:\/\/doi.org\/10.3390\/jcm15197540","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]}}}